Increased risk of squamous cell carcinoma in junctional epidermolysis bullosa

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 5, 2004, Pages 521-526

  Mallipeddi, R ^a   Keane, F M ^a   McGrath, J A ^a   Mayou, B J ^b   Eady, Robin A J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

Blister; Genodermatosis; Laminin 5; Scar; Skin cancer

Indexed keywords

LAMININ;

ADULT; AGED; CANCER RISK; CARBON DIOXIDE LASER; CASE REPORT; CHRONIC INFLAMMATION; EPIDERMOLYSIS BULLOSA; EXCISION; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; SKIN SCAR; SPLIT THICKNESS SKIN GRAFT; SQUAMOUS CELL CARCINOMA; TRANSMISSION ELECTRON MICROSCOPY; TUMOR DIFFERENTIATION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; EPIDERMOLYSIS BULLOSA, JUNCTIONAL; FATAL OUTCOME; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; RISK FACTORS; SKIN NEOPLASMS;

EID: 4544361513     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00968.x     Document Type: Review

References (47)

1. Fine JD, Eady RAJ, Bauer EA et al. Revised classification system for inherited epidermolysis bullosa: report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol 2000; 42: 1051-1066.
2. Herlitz G. Kongenitaler, nicht syphilitischer pemphigus: Eine ubersicht nebst beschreibung einer neuen krankheitsform. Acta Pediatr 1935; 17: 315-371.
3. Hintner H, Wolff K. Generalized atrophic benign epidermolysis bullosa. Arch Dermatol 1982; 118: 375-384.
4. Paller AS, Fine JD, Kaplan S, Pearson RW. The generalized atrophic benign form of junctional epidermolysis bullosa. Experience with four patients in the United States. Arch Dermatol 1986; 122: 704-710.
5. Tidman MJ, Eady RAJ. Hemidesmosome heterogeneity in junctional epidermolysis bullosa revealed by morphometric analysis. J Invest Dermatol 1986; 86: 51-56.
6. McMillan JR, McGrath JA, Tidman MJ, Eady RAJ. Hemidesmosomes show abnormal association with the keratin filament network in junctional forms of epidermolysis bullosa. J Invest Dermatol 1998; 110: 132-137.
7. Kivirikko S, McGrath JA, Baudoin C et al. A homozygous nonsense mutation in the alpha 3 chain gene of laminin 5 (LAMA3) in lethal (Herlitz) junctional epidermolysis bullosa. Hum Mol Genet 1995; 4: 959-962.
8. Aberdam D, Galliano ME, Vailly J et al. Herlitz's junctional epidermolysis bullosa is linked to mutations in the gene (LAMC2) for the gamma 2 subunit of nicein/kalinin (LAMININ 5). Nat Genet 1994; 6: 299-304.
9. Pulkkinen L, Christiano AM, Gerecke DR et al. A homozygous nonsense mutation in the beta 3 chain gene of laminin 5 (LAMB3) in Herlitz junctional epidermolysis bullosa. Genomics 1994; 24: 357-360.
10. McGrath JA, Gatalica B, Christiano AM et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a transmembrane hemidesmosomal collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet 1995; 11: 83-86.
11. McGrath JA, Pulkkinen L, Christiano AM et al. Altered laminin 5 expression due to mutations in the gene encoding the beta 3 chain (LAMB3) in generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 1995; 104: 467-474.
12. Ashton GHS, Sorelli P, Mellerio JE et al. Alpha 6 beta 4 integrin abnormalities in junctional epidermolysis bullosa with pyloric atresia. Br J Dermatol 2001; 144: 408-414.
13. Inoue M, Tamai K, Shimizu H et al. A homozygous missense mutation in the cytoplasmic tail of beta4 integrin, G931D, that disrupts hemidesmosome assembly and underlies non-Herlitz junctional epidermolysis bullosa without pyloric atresia? J Invest Dermatol 2000; 114: 1061-1064.
14. Marjolin JN. Ulcère. In: Dictionnaire de Medecine, Vol. 21. Bechet, Paris, 1828: 31-50.
15. Fine JD, Johnson LB, Suchindran C et al. Cancer and inherited epidermolysis bullosa: lifetable analyses of the national epidermolysis bullosa registry study population. In: Fine JD, Bauer EA, McGuire J, Moshell A, eds. Epidermolysis Bullosa. Clinical, Epidemiologic, and Laboratory Advances, the Findings of the National Epidermolysis Bullosa Registry. The Johns Hopkins University Press, Baltimore, 1999: 175-192.
16. Cleaver JE, Crowley E. UV damage, DNA repair and skin carcinogenesis. Front Biosci 2002; 7: 1024-1043.
17. Lotem M, Raben M, Zeltser R et al. Kindler syndrome complicated by squamous cell carcinoma of the hard palate: successful treatment with high-dose radiation therapy and granulocyte-macrophage colony-stimulating factor. Br J Dermatol 2001; 144: 1284-1286.
18. Parker SC, Schofield OMV, Black MM, Eady RAJ. Non-lethal junctional epidermolysis bullosa complicated by squamous cell carcinoma. In: Priestley GC, Tidmann MJ, Weiss JB, Eady RAJ, eds. Epidermolysis Bullosa: a Comprehensive Review of Classification Management and Laboratory Studies. DEBRA, Crowthorne, 1990: 103-106.
19. Monk BE, Pembroke AC. Epidermolysis bullosa with squamous cell carcinoma. Clin Exp Dermatol 1987; 12: 373-374.
20. Swensson O, Christophers E. Generalized atrophic benign epidermolysis bullosa in 2 siblings complicated by multiple squamous cell carcinomas. Arch Dermatol 1998; 134: 199-203.
21. Weber F, Bauer JW, Sepp N et al. Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa. Acta Derm Venereol 2001; 81: 189-192.
22. Ridley CM. Epidermolysis bullosa with unusual features: inverse type. Proc R Soc Med 1977; 70: 576-577.
23. Matsui C, Nelson CF, Hernandez GT et al. Gamma 2 chain of laminin-5 is recognized by monoclonal antibody GB3. J Invest Dermatol 1995; 105: 648-652.
24. Stouthamer A, Nieboer C, Van Der Waal RI et al. Normal expression of the 19-DEJ-1 epitope in two siblings with late-onset junctional epidermolysis bullosa. Br J Dermatol 2001; 144: 1054-1057.
25. Pulkkinen L, Meneguzzi G, McGrath JA et al. Predominance of the recurrent mutation R635X in the LAMB3 gene in European patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy. J Invest Dermatol 1997; 109: 232-237.
26. McGrath JA, Christiano AM, Pulkkinen L et al. Compound heterozygosity for nonsense and missense mutations in the LAMB3 gene in nonlethal junctional epidermolysis bullosa. J Invest Dermatol 1996; 106: 1157-1159.
27. Goodwin P, Eady R. A case of? epidermolysis bullosa. Clin Exp Dermatol 1977; 2: 409-412.
28. Mallipeddi R. Epidermolysis bullosa and cancer. Clin Exp Dermatol 2002; 27: 616-623.
29. McGrath JA, Schofield OMV, Mayou BJ et al. Epidermolysis bullosa complicated by squamous cell carcinoma: report of 10 cases. J Cutan Pathol 1992; 19: 116-123.
30. Hosokawa K, Yoshitatsu S, Kakibuchi M et al. Simultaneous manifestation of squamous cell carcinoma in identical twins with epidermolysis bullosa. Plast Reconstr Surg 1998; 102: 448-449.
31. Schwartz RA, Birnkrant AP, Rubenstein DJ et al. Squamous cell carcinoma in dominant-type epidermolysis bullosa. Cancer 1981; 47: 615-620.
32. Christiano AM, Crollick J, Pincus S, Uitto J. Squamous cell carcinoma in a family with dominant dystrophic epidermolysis bullosa: a molecular genetic study. Exp Dermatol 1999; 8: 146-152.
33. Reed WB, College J, Francis MJO et al. Epidermolysis bullosa dystrophica with epidermal neoplasms. Arch Dermatol 1974; 110: 894-902.
34. Pellicano R, Fabrizi G, Cerimele D. Multiple keratoacanthomas and junctional epidermolysis bullosa. A therapeutic conundrum. Arch Dermatol 1990; 126: 305-306.
35. Verrando P, Hsi BL, Yeh CJ et al. Monoclonal antibody GB3, a new probe for the study of human basement membranes and hemidesmosomes. Exp Cell Res 1987; 170: 116-128.
36. Aberdam D, Aguzzi A, Baudoin C et al. Developmental expression of nicein adhesion protein (laminin-5) subunits suggests multiple morphogenic roles. Cell Adhes Commun 1994; 2: 115-129.
37. Glazier DB, Zaontz MR. Epidermolysis bullosa: a review of the associated urological complications. J Urol 1998; 159: 2122-2125.
38. Lohi J. Laminin-5 in the progression of carcinomas. Int J Cancer 2001; 94: 763-767.
39. Goldberg GI, Eisen AZ, Bauer EA. Tissue stress and promotion. Possible relevance to epidermolysis bullosa. Arch Dermatol 1988; 124: 737-741.
40. Smoller BA, McNutt NS, Carter DM et al. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis. Arch Dermatol 1990; 126: 78-83.
41. Arbiser JL, Fine JD, Murrell D et al. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Mol Med 1988; 4: 191-195.
42. Tyring SK, Chopra V, Johnson L et al. Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Arch Dermatol 1989; 125: 797-800.
43. Chopra V, Tyring SK, Johnson L et al. Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production. J Clin Immunol 1990; 10: 321-329.
44. Phillips TJ, Salman SM, Bhawan J, Rogers G. Burn scar carcinoma. Diagnosis and management. Dermatol Surg 1998; 24: 561-565.
45. Dupree MT, Boyer JD, Cobb MW. Marjolin's ulcer arising in a burn scar. Cutis 1998; 62: 49-51.
46. Alconchel MD, Olivares C, Alvarez R. Squamous cell carcinoma, malignant melanoma and malignant fibrous histiocytoma arising in burn scars. Br J Dermatol 1997; 137: 793-798.
47. McGrath JA, Ashton GH, Mellerio JE et al. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame shipping of exons containing nonsense or frame shift mutations. J Invest Dermatol 1999; 113: 314-321.